Paroxetine for the Prevention of IFN-Alpha Associated Depression in Patients With Chronic Hepatitis C

Trial Profile

Paroxetine for the Prevention of IFN-Alpha Associated Depression in Patients With Chronic Hepatitis C

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2013

At a glance

  • Drugs Paroxetine (Primary)
  • Indications Depression
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Nov 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT00209118).
    • 05 Nov 2010 New trial record.
    • 01 May 2007 Results published in Alimentary Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top